Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05878938 | A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5) | PHASE3 | COMPLETED | 61 | — | — | Jun 26, 2023 | Jul 19, 2024 | Dec 8, 2025 | 36 | United States, Austria +10 |
Measured as count of events.
| Arm | Type | Description |
|---|---|---|
| NNC0365-3769 (Mim8) PPX | EXPERIMENTAL | Participants will receive Mim8 prophylaxis (PPX) subcutaneous (s.c.) injection using a prefilled fixed dose DV3407-C1 pen-injector. |
| Name | Type | Description |
|---|---|---|
| NNC0365-3769 (Mim8) PPX | DRUG | Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks. |
Inclusion Criteria: 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. 2. Male or female with diagnosis of congenital haemophilia A of a...